Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Regulatory News (OVB)

  • There is currently no data for OVB

Directorate Change

15 Jul 2024 07:00

RNS Number : 2941W
Ovoca Bio PLC
15 July 2024
 

 

Ovoca Bio PLC

15 July 2024

 

This announcement contains inside information

 

Ovoca Bio plc

 

("Ovoca" or the "Company")

 

Ovoca Bio Announces Management Change

 

Dublin, Ireland, 15 July 2024 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, announces the following change in management and board composition. Kirill Golovanov has informed the Board of his intention to resign from his role as Chief Executive and an Executive Director of the Company, with effect from 1 August 2024. At the same time, Timothy McCutcheon will become Chief Executive Officer and remain as a Director of the Company.

 

Mr. Golovanov stated: "It has been a pleasure to serve as Executive Director of Ovoca for the past 12 years and it is with a heavy heart that I am leaving the Company. However, with the end of the Company's efforts to develop Orenetide, I believe now is the appropriate time for Ovoca to have new leadership and change direction. I wish Mr. McCutcheon the best in his efforts to re-position Ovoca and I wish all the team at Ovoca the very best for the future."

 

Mr. McCutcheon commented: "I would like to thank Mr. Golovanov for his long service to the Company, and I know it was a difficult decision for him to decide to step down. I am excited to take on the role of Chief Executive of Ovoca and to work with my colleagues to deliver future value for shareholders, both through realizing the value from our existing assets and also exploring new opportunities where we can leverage our existing skills and knowledge. I look forward to updating stakeholders on our progress in the coming months."

 

In addition to the management change, Mr. McCutcheon has acquired from Mr. Golovanov his stake in Ovoca, totaling 19,506,203 ordinary shares.

 

Mr. McCutcheon is a capital markets professional and corporate manager with over 25 years' business experience. He has served as CEO and Director of several public natural resource companies with assets in Canada, Chile, Kyrgyzstan, Ghana, Mali, Russia, Slovakia and USA. Prior to his role as company manager, he was an award winning equity analyst at a major brokerage firm and founder of a boutique merchant bank specializing in the mining sector. Mr. McCutcheon obtained his BA his MBA in finance from Columbia University.

 

End

 

For further information:

 

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com

 

Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)

Ivan Murphy / Daragh O'Reilly

Tel: +353 1 679 6363

 

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUUSVRSOUBAAR
Date   Source Headline
5th Feb 20267:00 amRNSChange of Name
28th Jan 20268:00 amRNSReadmission - Ovoca Bio PLC
28th Jan 20267:00 amRNSFirst Day of Dealings on AIM
27th Jan 20262:32 pmRNSResult of Meeting
31st Dec 20258:00 amRNSSchedule One - Ovoca Bio Plc
31st Dec 20258:00 amRNSSchedule One - Ovoca Bio Plc
31st Dec 20257:00 amRNSNotice of AGM
31st Dec 20257:00 amRNSPublication of Admission Document
31st Dec 20257:00 amRNSPublication of Admission Document
31st Dec 20257:00 amRNSNotice of AGM
13th Nov 20257:00 amRNSChange of Broker
30th Sep 20251:09 pmRNSReplacement Half Year Report
30th Sep 20257:00 amRNSHalf-year Report
26th Jun 20257:00 amRNSPublication of 2024 Annual Report
5th Jun 20257:00 amRNSDelisting from Euronext Growth Exchange
7th May 20257:30 amRNSSuspension - Ovoca Bio plc
7th May 20257:00 amRNSProposed Acquisition, Disposal & Reverse Takeover
3rd Mar 20252:00 pmRNSManagement Changes
18th Dec 20246:00 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM
11th Oct 20245:30 pmRNSHolding(s) in Company
9th Oct 20245:45 pmRNSSale of Treasury Shares
25th Sep 20247:00 amRNSHalf-year Report
2nd Sep 20242:30 pmRNSConsultancy Agreement
15th Jul 20247:00 amRNSDirector/PDMR Shareholding
15th Jul 20247:00 amRNSDirectorate Change
28th Jun 20247:00 amRNSAnnual Financial Report
23rd Jan 20247:00 amRNSHolding(s) in Company
1st Dec 202312:00 pmRNSResult of AGM
7th Nov 20239:15 amRNSNotice of AGM
28th Sep 20237:00 amRNSInterim Results
31st Aug 20237:00 amRNSSummary Results of Phase II Study for Orenetide
30th Jun 20237:00 amRNSAnnual Financial Report
12th Jun 20237:00 amRNSUpdate on Completion Timelines for Phase II Study
16th Mar 20234:35 pmRNSPrice Monitoring Extension
16th Mar 20232:05 pmRNSSecond Price Monitoring Extn
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 20239:05 amRNSSecond Price Monitoring Extn
16th Mar 20239:00 amRNSPrice Monitoring Extension
8th Mar 20237:00 amRNSDisposal of Russian Assets
14th Feb 20234:41 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20232:05 pmRNSSecond Price Monitoring Extn
14th Feb 20232:00 pmRNSPrice Monitoring Extension
13th Feb 20239:00 amRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
28th Oct 20227:00 amRNSResult of AGM
6th Oct 20222:30 pmRNSNotice of AGM
30th Sep 20227:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.